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Abstract
Background: Fungal infections are diagnosed increasingly often in patients affected by hematological diseases and
their mortality has remained high. The recent development of new antifungal drugs gives the clinician the
possibility to assess the combination of antifungal drugs with in-vitro or in animal-model synergistic effect.
Methods: We analyzed retrospectively the safety and efficacy of caspofungin-based  combination therapy in 40
children and adolescents,  most of them were being treated for a malignant disease, who developed invasive
aspergillosis (IA) between November 2002 and November 2005.
Results: Thirteen (32.5%) patients developed IA after hematopoietic stem cell transplantation (HSCT), 13 after
primary diagnosis, usually during remission-induction chemotherapy, and 14 after relapse of disease. Severe
neutropenia was present in 31 (78%) out of the 40 patients. IA was classified as probable in 20 (50%) and
documented in 20 (50%) patients, respectively. A favorable response to antifungal therapy was obtained in 21
patients (53%) and the probability of 100-day survival was 70%. Different, though not significant, 100-day survival
was observed according to the timing of diagnosis of IA: 51.9% after HSCT; 71.4% after relapse; and 84.6% after
diagnosis of underlying disease, p 0.2. After a median follow-up of 0.7 years, 20 patients are alive (50%). Overall,
the combination therapy was well tolerated. In multivariate analysis, the factors that were significantly associated
to a better overall survival were favorable response to antifungal therapy, p 0.003, and the timing of IA in the
patient course of underlying disease, p 0.04.
Conclusion: This study showed that caspofungin-based combination antifungal therapy is an effective therapeutic
option also for pediatric patients with IA. These data need to be confirmed by prospective, controlled studies.
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Background
Fungal infections, especially those caused by Aspergillus
spp. or by other filamentous fungi, are diagnosed increas-
ingly often in patients affected by hematological dis-
eases.[1,2] Despite the introduction of liposomal and
lipid formulations of amphotericin B during the 1990's,
infection-related mortality of invasive mycoses has
remained high.[3,4] The recent development of new anti-
fungal drugs, such as voriconazole and caspofungin gives
the clinician more therapeutic options both for first-line
and for salvage therapy of invasive mycoses.[5,6] Notably,
caspofungin has a different target of action with respect to
the polyenes and triazoles, i.e. it inhibits the synthesis of
a component of the fungal cell wall, namely beta-1,3-D-
glucan; and data obtained either in-vitro  or in animal
models have shown that the combination of caspofungin
with either amphotericin B or voriconazole may exert a
synergistic effect. [7-9] On the basis of these premises, sev-
eral authors have explored the use of caspofungin in com-
bination with either liposomal amphotericin B,
itraconazole or voriconazole in patients with invasive
mycoses refractory to first-line treatment, with reported
response rates ranging between 42 and 60% in the largest
series. [10-14] Despite that published pediatric data on
the use of caspofungin in combination with other sys-
temic antifungal drugs are limited to single-center experi-
ence [15-17], recent multicenter studies showed that, as in
adults, this therapeutic strategy is being increasingly
adopted by pediatric centers. [18,19]
In this study, we report the data collected among centers
belonging to the Italian Association of Pediatric Hematol-
ogy Oncology (AIEOP) to investigate the safety and effi-
cacy of caspofungin in combination with other systemic
antifungal drugs.
Methods
From January 2002 to December 2003, the AIEOP centres
performed a prospective surveillance study aimed at
assessing the incidence and outcome of invasive fungal
infection in children and adolescents affected by hemato-
logical and oncological diseases. [19] During the first year
of study, it was noted that caspofungin was often used in
combination with other antifungal drugs both as front-
line and rescue treatment for invasive aspergillosis (IA).
Therefore, a registry was established starting in November
2002 in order to collect prospectively the data on the anti-
fungal combination therapy for IA in children. Each inves-
tigator sent to the principal investigator (S.C.) the main
clinical and microbiological data of the patients develop-
ing IA and treated within 30 days from diagnosis with
combination antifungal therapy. Informed consent was
obtained from parents or patient's legal representatives.
Recruitment of patients was closed on November 2005
and follow-up data are as 31st January 2006.
The eligibility criteria were as follows: pediatric hemato-
logical or oncological patients treated with a caspofungin-
based combination antifungal therapy for proven or prob-
able IA diagnosed whilst on chemotherapy or after hemat-
opoietic stem cell transplantation (HSCT). Since this was
a retrospective study, the main objectives of the study
were the definition of a favorable response rate, 100-day
survival and overall survival (OS) of patients treated with
a caspofungin-based combination therapy, as well as the
safety and toxicity of the combination regimen.
Management of febrile patients: neutropenic and HSCT
patients were nursed in reverse-isolation or high-effi-
ciency particulate-filtered air (HEPA) rooms, respectively.
Published recommendations were used for diagnosis and
treatment of febrile episodes [20,21], i.e a) ensuring
prompt clinical and microbiological evaluation of
patients with a search for clinical foci of infection by phys-
ical examination, chest X-ray, abdominal ultrasound (if
appropriate), cultures of peripheral and central venous
catheter (CVC) blood, and, if indicated, mouth and CVC
exit-site swabs, stool and urine cultures; b) intravenous
administration of broad-spectrum antibiotic therapy for
at least 72–96 hours and, in case of persistence of fever, c)
a thorough re-assessment of the patient and introduction
of empiric antifungal therapy based on either amphoter-
icin B or a lipid/liposomal derivative.[22,23] In recent
years, these guidelines have been implemented in patients
considered at higher risk of invasive fungal infection,
through the use of chest computed tomography (CT)
scanning early in the course of the febrile episode for
patients not responding to broad spectrum antibiotic
therapy and the determination of serum galactomannan.
[24-26] The following groups of patients underwent this
more thorough diagnostic work-up at the participating
AIEOP centers: patients with acute myeloid leukemia;
patients with de novo or relapsed acute lymphoblastic
leukemia while on induction or re-induction therapy;
patients undergoing HSCT; patients with prolonged
severe neutropenia or on steroid therapy.
For the purposes of the study, the caspofungin-based
combination therapy was considered as introduced early
(group A) or late (group B) if started within or after 7 days
from diagnosis of IA, respectively.
Definitions: according to the timing of diagnosis of IA, we
distinguished 3 groups of IA: a) those occurring after
HSCT, if the patient have been transplanted before IA and,
in case of malignant disease, did not experience a subse-
quent relapse; b) those diagnosed after relapse, if the
patient had relapsed prior to the diagnosis of IA; and c)
those developing IA during remission-induction chemo-
therapy for newly diagnosed malignancy, or in case of
non-malignant disease, after diagnosis of underlying dis-BMC Infectious Diseases 2007, 7:28 http://www.biomedcentral.com/1471-2334/7/28
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ease. Regarding the status of the underlying malignant dis-
ease at the time of diagnosis of IA, we distinguished 2
groups of patients: those in complete remission, and
those without an adequate control of disease, i.e. other
remission status.
Severe neutropenia was defined by an absolute neutrophil
count < 0.5 × 109/l. Drug-related side effects, organ toxic-
ity and complications after HSCT were defined according
to standard criteria.[27]
Proven and probable IA were defined according to inter-
nationally accepted criteria. [28] For the purposes of this
study, the caspofungin-based combination therapy was
considered as primary therapy if the patients were not
receiving any mould-active antifungal drug or were on
prophylaxis with fluconazole or itraconazole; and as sal-
vage therapy if the patients were receiving empirically or
therapeutically any mould-active antifungal mono-
therapy, at diagnosis of IA, respectively.
The response to antifungal treatment was defined on the
basis of the Denning criteria [29], as follows: complete
response (CR) was the resolution of all clinical signs and
symptoms attributable to IA, together with complete or
very nearly complete radiographic resolution (≥ 90%);
partial response (PR) was a major improvement or resolu-
tion of the attributable clinical signs and symptoms
together with at least a 50% improvement in radiological
signs; stable response (SR) was consistent with some but
less than 50% radiological improvement; and Failure (F)
was progression of, or death from, IA. Favorable (or
major) response comprised both CR and PR.
Statistical analysis
Demographic, clinical and microbiological characteristics
of patients and infectious episodes were collected through
specific case-report forms filled-in by the investigators;
data were stored on an Access 97 data base (Microsoft,
Seattle, WA, USA). Analysis used January 31st 2006 as the
reference date, i.e., the day at which all centers locked data
on patient outcomes. Where appropriate, the characteris-
tics of the patients and of infectious episodes were com-
pared using chi-square or Fisher's exact test for categorical
variables.
The end points of the study were: rate of favorable
response, i.e. complete and partial response; 100-day sur-
vival, OS, safety and toxicity of the antifungal combina-
tion therapy.
One-hundred-day survival and OS were calculated from
the date of diagnosis of invasive fungal infection (IFI) to
100 days after diagnosis of IFI, or to the date of death due
to any cause or to the date of last follow-up, respectively,
by the Kaplan-Meier method. Differences between
patients who received a caspofungin-based combination
therapy as first line (group A) or rescue therapy (group B)
were compared by the log-rank test.
The following variables were included in the analysis of
prognostic factors predicting favorable response, 100-day
survival and OS: patient gender (M vs. F); median age at
diagnosis of IA; occurrence of IA after diagnosis, after
relapse or after HSCT, respectively; presence of severe neu-
tropenia at time of diagnosis of IA; single organ vs multi-
ple organ involvement; type of IA (documented vs.
probable); surgical treatment of IA; early introduction of
caspofungin, i.e. group A vs. group B; and caspofungin-
based combination therapy given as primary vs. salvage
treatment. Moreover, the rate of favorable response to
antifungal therapy was included in the analysis of prog-
nostic factors for 100-day survival and OS. The variables
proving significant in univariate analysis were included in
a multivariate analysis: favorable response and 100-day
survival were assessed by a stepwise logistical regression
analysis, whilst OS was determined by a Cox regression
analysis. All reported p values are 2-sided, and a signifi-
cance level of α = 0.05 was used. The statistical analysis
was performed using the SAS statistical program (SAS
Institute, Cary, NC, Version 8.2).
Results
The main demographic and clinical characteristics of the
patients are shown in table 1. During the study period, 40
patients, 21 males and 19 females, were recruited, median
age at diagnosis being 11.1 years (range 1.2–17.9 years).
Thirteen (32.5%) patients developed IA after allogeneic
unrelated (10) or related (3) HSCT. The median time
from HSCT to IA was 14 days (range 1–308). In the
month before the diagnosis of IA, 10 and 2 patients had
been treated with steroids at median dose of 2 mg/kg/day
for acute GVHD (grade I-II, 5; grade III-IV, 5) and for
extended chronic GVHD, respectively.
In 13 patients (32.5%), IA occurred after a median time of
74 days (range 13–318) from the diagnosis of underlying
disease whilst in 14 patients (35%) IA occurred after a
median time of 74 days (range 7–261) from relapse.
Characteristics of episodes of fungal infections: Table 2 sum-
marizes the main data on episodes of IA. They were classi-
fied as probable in 20 (50%) and proven in 20 (50%)
patients, respectively. In proven IA, the species identifica-
tion obtained by culture was as follows: Aspergillus fumig-
atus, 7; Aspergillus flavus, 3; in the remaining 10 episodes
of proven IA, histopathology on tissue sample showed the
presence of filamentous fungi consistent with Aspergillus
spp.BMC Infectious Diseases 2007, 7:28 http://www.biomedcentral.com/1471-2334/7/28
Page 4 of 10
(page number not for citation purposes)
Severe neutropenia was present at diagnosis of IA in 31
patients (78%) and lasted for a median time of 29 days,
range 2–251. The median lymphocyte count at time of
diagnosis of IA was 170 × 109/L, range 0–5,710.
In 27 (68%) episodes, the patient was on steroid therapy
at diagnosis of IA, whilst in 14 (35%) episodes the patient
was receiving either cyclosporine-A or tacrolimus.
The lungs were the most frequent organ affected, pulmo-
nary IA being involved in 39 (98%) out of the 40 children
enrolled in this analysis. Most patients, 29 (73%), had
involvement of a single site: lung, 28; skin, 1; whilst 11
patients (27%) had 2 or more organs involved. In this last
group, central nervous system involvement was present in
4 patients.
Thirty-three of 40 patients (82.5%) were on antifungal
treatment before starting the combination therapy, as fol-
lows: 13 patients were on prophylaxis with fluconazole
(12 patients) or itraconazole (1 patient) for a median time
of 28 days (range 10–50); 6 patients were on liposomal
amphotericin-B as empiric treatment of fever and neutro-
penia for a median time of 10 days (range 3–43); and 14
patients were on liposomal amphotericin-B (10 patients)
or caspofungin (3 patients) or voriconazole (1 patient) as
first-line treatment of IA for a median time of 8 days
(range 3–56). The reasons for switching to combination
Table 1 : Main demographic and clinical characteristics of patients  included in this study.
Group A Group B Total
Number of patients 22 18 40
Gender
Male 14 7 21
Female 81 11 9
Age at IA diagnosis
Median (years) 11.94 8.64 11.05
Range (1.3–17.2) (1.18–17.9) (1.18–17.9)
Underlying disease
ALL-AML 15 13 28
CML 20 2
NHL+HD 22 4
MDS 21 3
Non-malignant diseases 1 2 3
IA after relapse of underlying disease 951 4
Interval from relapse to IA (days)
Median 69 105 74
Range (18–174) (7–261) (7–261)
IA after allogeneicHSCT 761 3
Source of SC
BM 741 1
PB /1 1
CB /1 1
Interval from HSCT to IA (days)
Median 14 15 14
Range (4–308) (0–54) (0–308)
IA after diagnosis of underlying disease 671 3
Interval from diagnosis to IA (days)
Median 115 46 74
Range (15–318) (13–76) (13–318)
Remission status of underlying disease * 21 16 37
Complete remission 6 7 13
Other status 15 9 24
Group A comprises patients given caspofungin-based combination therapy  starting within 7 days from diagnosis of IA;  Group B consists of patients 
given caspofungin-based combination therapy starting after 7 days from diagnosis of IA.
IA, invasive aspergillosis; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin Lymphoma; HD, Hodgkin 
Lymphoma;  MDS, myelodysplastic syndrome; HSCT, hematopoietic stem cell transplantation; BM, bone marrow; PB, peripheral blood; CB, cord 
blood; Other status: refractory or progressive disease; *only for the 37 children with malignant diseases.BMC Infectious Diseases 2007, 7:28 http://www.biomedcentral.com/1471-2334/7/28
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antifungal therapy in the patient on antifungal therapy
were progression of disease or failure to improve clinically
or radiographically. The remaining 7 patients were started
on combination therapy as first-line treatment of IA.
Fourteen patients (35%) underwent elective surgical
resection of the fungal lesions, from lungs 11 (27.5%) or
from other organs 3 (7.5%), after a median time of 26
days (range 0–218 days) from diagnosis of IA.
Response to therapy and survival: the median duration of any
combination of antifungal therapy was 29 days (range 3–
382 days). Considering the 36 patients who received at
least seven days of combination therapy, 18 patients
(50%) received the combination of caspofungin and lipo-
somal amphotericin B for a median time of 26 days (range
7–90 days), 9 patients (25%) received the combination of
caspofungin and voriconazole for a median of 38 days
(range 12–94 days) and the remaining 9 patients (25%)
received sequentially both combinations, for a median of
19 days (range 7–84 days). The dosages used were as fol-
lows: caspofungin, 70 mg/m2 the first day, followed by 50
mg/m2/day; voriconazole, 2 × 6 mg/kg the first day, fol-
lowed by 2 × 4 mg/kg/day; and liposomal amphotericin B,
3–5 mg/kg/day. No difference was found in terms of out-
come at 100 days from diagnosis of IA in these 3 groups
of patients, a favorable response being observed in 39%,
56% and 56%, respectively, (p NS).
At 100–days from diagnosis of IA, complete response was
observed in 12 patients (30%), partial response in 9
patients (22.5%), stable response in 4 patients (10%) and
failure in 2 (5%) patients. Noteworthy, 2 of 4 patients
with CNS involvement had significant clinical improve-
ment and were classified as partial responder. Overall, a
favourable response was documented in 21 of 40 patients
(53%). One-hundred-day survival was 70%, confidence
interval (C.I.) being 55–84. Figure 1a shows that no differ-
Table 2: Main data on invasive mycosis.
Group A Group B Total
Type of mycosis
Probable 13 7 20
Documented 9 11 20
Severe neutropenia at diagnosis of IFI 17 14 31
Lymphocyte count at diagnosis of IFI
Median (× 109/L) 100 200 170
Range (0–2230) (0–5710) (0–5710)
IS therapy at IFI
Steroids 14 13 27
CSA or FK 506 * 8 6 14
Number of organ involved
1 17 12 29
2 34 7
≥ 3 22 4
Type of organ involvement
Lung 22 17 39
CNS 31 4
Skin 12 3
URA 20 2
Heart 02 2
Other 16 7
Surgery 77 1 4
Site
Lung 65 1 1
other 12 3
Time from diagnosis of IA to surgery
Median (days) 27 20 26
range (16–218) (0–81) (0–218)
Group A comprises patients given caspofungin-based combination therapy starting within 7 days from diagnosis of IA; Group B consists of patients 
given caspofungin-based combination therapy starting after 7 days from diagnosis of IA.
IS, immunosuppressive drugs; IFI, invasive fungal infection; CNS, central nervous system; URA, upper respiratory airways; *with or without other IS 
drugs; CSA, cyclosporine-A, FK 506, tacrolimus.BMC Infectious Diseases 2007, 7:28 http://www.biomedcentral.com/1471-2334/7/28
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ence was observed for the 100-day survival according to
the timing of adoption of a caspofungin-based combina-
tion therapy: group A, 70.4%, C.I. 56–85; vs group B,
74.1%, C.I. 58–91, p 0.8. Moreover, 100-day survival
resulted different, though not significant, according to the
timing of diagnosis of IA: 84.6% (C.I. 65–100) for IA
occurring after diagnosis of underlying disease; 71.4%
(47.8–95.1) for IA occurring after relapse of underlying
disease; and 51.9% (C.I. 23.9–80) for IA occurring after
HSCT, p 0.2 (figure 1b).
After a median follow-up of 0.7 years (range 100 days –
3.1 years), 20 patients (50%) are alive. The probability of
OS for the whole group of patients was 44%, C.I. 27–61.
Figure 1c shows that OS probability was significantly bet-
ter in patients who developed IA after diagnosis of under-
lying disease, 48% (C.I. 7–89), as compared with those
experiencing IA either after relapse, 20.9%, (C.I. 2–40), or
after HSCT, 32.4% (C.I. 9–56), respectively, p 0.007.
Sixteen of 20 patients (80%) who died had active aspergil-
losis before death on the basis of clinical, radiological and
microbiological investigations; 8 of these 16 patients
(50%) were either not in remission of their underlying
disease or had clinical and/or hematological signs of pro-
gression of their primary disease. The other causes of
death were not related to IA but to progression of the pri-
mary malignant disease, 1 (5%), graft-versus-host disease,
2 (10%) and septic shock, 1 (5%).
Analysis of factors predictive of favorable response, 100-survival
and OS: table 3 shows the results of analysis on potentially
prognostic factors. No factor was found to predict a
favourable response in univariate and multivariate analy-
sis.
Factors significantly associated in univariate analysis with
a better 100-day survival and OS were type of IA, surgical
treatment, and the achievement of a favourable response
rate.
In multivariate analysis, no factor was predictive for 100-
day survival whilst the favorable response to antifungal
therapy and the occurrence of IA after diagnosis of under-
lying disease vs. after HSCT or relapse resulted signifi-
cantly associated to better OS, p 0.03 and p 0.04,
respectively.
Safety and toxicity: the antifungal combination therapy was
generally well tolerated and no severe renal or liver
impairment (grade II-IV WHO toxicity) attributable to the
antifungal drugs was observed. Two patients were with-
drawn whilst on voriconazole, for bradi-arrhythmia, 1;
and diarrhea and bone pain, 1, respectively. One patient
developed a transient skin rash while on caspofungin
therapy; this side effect was controlled with symptomatic
drugs and did not require withdrawal of caspofungin.
Discussion
Despite recent advances in diagnosis and treatment, IA
still represent an important cause of mortality in immune-
compromised hosts. [2-5] In this last few years, a new
strategy of antifungal therapy, using a combination of
antifungal drugs, has been an important subject of inves-
tigation, and as a whole, the available experimental and
clinical results suggest that combination antifungal ther-
apy may improve patient outcome. [30] The recent intro-
duction of new molecules with broad spectrum of activity,
low toxicity, and novel mechanisms of action such echi-
nocandin is certainly favoring this strategy. There are sev-
eral arguments that justify the strategy of combining
antifungal drugs to optimize therapy such as the in vitro
data showing a potential for a synergistic effect, broader
spectrum of activity and a decreased risk of emergence of
resistant strains; and the absence of a negative or harmful
effect when an azole is combined with a polyene or an
echinocandin in animal models of IA. [30-34]
Recent reports have suggested that combination therapy
with the new antifungal drugs may be more effective that
antifungal mono-therapy, raising the hope that new
standards for the treatment of invasive mycoses may
become available in the near future. [10-15]
Our study represents the largest survey on the use of com-
bination antifungal therapy for IA in children and adoles-
cents. The first observation deriving from this study is that
the use of combination therapy is definitely increasing
compared with past practice. According to published data,
only 249 cases of combination antifungal therapy were
reported among 6,281 total cases of IA diagnosed in the
period from 1966 to 2001. [30] In contrast, we collected
40 episodes of combination therapy in the 36-month
duration of this study (1.1 episodes/month). A recent pro-
spective multicenter surveillance survey from 2001 to
2002 among the AIEOP centers showed that 49% of epi-
sodes of fungemia, or proven, probable and possible
mycoses have been treated with combination therapy
[19].
Differently from other authors [10,11], we excluded from
analysis patients with a lower certainty of IA, namely chil-
dren fulfilling the criteria of possible IA, as we reasoned
that these cases should be considered not sufficiently reli-
able to assess the efficacy of an antifungal drug. As a
whole, only 17 patients with diagnosis of possible IA were
treated with combination therapy during the study period
(data not shown).BMC Infectious Diseases 2007, 7:28 http://www.biomedcentral.com/1471-2334/7/28
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a) No difference was found in the 100-day survival between the patients of group A, who were started on a caspofungin-based  combination therapy within < 7 days from diagnosis of IA vs the patients of group B, who were started on a caspofungin-based  combination therapy after 7 days from diagnosis of IA Figure 1
a) No difference was found in the 100-day survival between the patients of group A, who were started on a caspofungin-based 
combination therapy within < 7 days from diagnosis of IA vs the patients of group B, who were started on a caspofungin-based 
combination therapy after 7 days from diagnosis of IA. b) and c) Kaplan-Meier estimate of 100-day survival and OS according to 
the timing of diagnosis of IA: IA after diagnosis of underlying disease vs IA after HSCT vs IA after relapse.
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Overall, the favorable response rate and 100-day survival
were 53% and 70% respectively, which are noteworthy if
one considers our high-risk population where 31 patients
(78%) had severe neutropenia; 27 patients (67.5%) had
IA after relapse of underlying disease or after HSCT; and
20 patients (50%) were refractoriness to empiric or first-
line antifungal therapy. Despite this, we obtained a
response rate and 100-survival superimposable to that
observed in two recent randomized studies where vorico-
nazole and liposomal amphotericin-B (3 mg/kg) were
used as first-line treatment for IA i.e. the favorable
response rate was 52.8% and 50%; and the 12-week sur-
vival 70.8% and 72%, respectively. [5,35] Moreover, com-
bination antifungal therapy was associated to a superior
successful outcome than previous studies with newer
agents used as salvage mono-therapy: amphotericin B-
lipid complex, 42% [36]; voriconazole 39% [29]; caspo-
fungin, 45%–44%. [37,38]Walsh et al. reported a favora-
ble response rate of 33% and 38% in children with either
hematological malignancy or given HSCT who received
voriconazole as rescue therapy for IA.[39] A recent pro-
spective, open-label, non-comparative study on 53 adults
reported the results of caspofungin given with other anti-
fungals as salvage therapy for IA refractory (87%) or intol-
erant (13%) to first-line antifungal therapy. Favorable
response at the end of combination therapy was 55%
whilst 12-week favorable response and survival rate was
49% and 55%, respectively [40]
The overall survival of 44% of our patients compared well
with that observed retrospectively by Abbasi et al. in 66
pediatric cancer patients cancer where 1-year mortality
was 85%; moreover, in that study lung involvement was
associated with poorer outcome.[41]
In patients given allogeneic HSCT, IA is still associated to
lower response to antifungal drugs and survival. This is
confirmed by recent study on adult HSCT patients, who
had been diagnosed with proven or probable IA in 2002,
that showed a discouraging 4-month survival of 34%. [42]
Table 3: Univariate and multivariate analysis of the factors associated with favorable response to antifungal therapy, 100-day survival 
and overall survival rate
Factors Favorable 
response rate
Univ P Multiv P 100-day-survival rate Univ P Multiv P OS rate Univar P Multiv P
Gender
M 11/21 1 15/21 0.8 9/21 0.3
F 10/19 13/19 11/19
Age (years) at IA
< the median 10/20 0.8 15/20 0.5 12/20  0.2
≥ the median 11/20 13/20 8/20
IA after:
HSCT/Relapse 12/27 0.1 17/27 0.3 10/27  0.02 0.048
Diagnosis 9/13 11/13 10/13 
ANC < 0.5 × 109/l
yes 16/31 1 21/31 0.7 14/31 0.5
no 5/9 7/9 6/9 
Number of organ affected:
Single organ 14/29  0.4 20/29 1 12/29  0.08
Multiple organs 7/11 8/11 8/11 
Type of IA
Probable IA 8/20  0.1 11/20 0.04 - 6/20 0.01
Documented IA 13/20 17/20 14/20 
Surgical treatment -
Yes 9/14 0.3 13/14 0.03 10/14  0.047
No 12/26 15/26  10/26 
Timing of caspofungin-based 
combination therapy
< 7 days from IA 13/22 0.4 17/22 0.3 10/22 0.5
≥ 7 days from IA 8/18 11/18 10/18
Combination therapy as:
Primary or 12/20 0.3 14/20 1 10/20 1
Salvage therapy 9/20 14/20 10/20
Favorable response
yes NE NE NE 21/21  < 0.001 - 16/21  < 0.001 0.003
no 7/19 4/19 
Univ.: univariate analysis; Multiv.: multivariate analysis; OS: overall survival; M: male; F: female; IA: invasive aspergillosis; ANC: absolute neutrophil 
count; NE.: not evaluated; BMC Infectious Diseases 2007, 7:28 http://www.biomedcentral.com/1471-2334/7/28
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We found a response rate and a 100-day survival of 44%
and 63% in patient with IA after HSCT or relapse that
compared well with the results observed for the same sub-
group of patients in the studies with voriconazole or
caspofungin as salvage mono-therapy [29,37]. Our results
are in line with those of Marr et al. who showed that com-
bination therapy with caspofungin and voriconazole in
HSCT patients gave a better 3-month survival than that
observed in a historical control group treated with vorico-
nazole alone.[13] However, the retrospective design of
this study did not allow to ascertain clearly if the combi-
nation caspofungin-based combination therapy was sig-
nificantly better than any other monotherapy without
caspofungin.
Neither the type of combination antifungal therapy nor
the early introduction of caspofungin-based combination
therapy had a significant effect on the response rate and
100-day survival. In the multivariate analysis, the only fac-
tors that resulted significantly associated to better overall
survival were the achievement of a favourable response to
antifungal treatment and the occurrence of IA after the
diagnosis of underlying disease.
Conclusion
This study has shown that the combination of caspofun-
gin with other antifungal drugs is effective and well toler-
ated also in pediatric patients with IA. Despite the
inclusion of patients with high-risk characteristics of poor
outcome, favorable response and 100-day survival were
not inferior to those reported for antifungal mono-ther-
apy with new antifungal drugs used as first-line or rescue
treatment for IA. The potential benefit of combination
antifungal therapy over mono-therapy needs to be inves-
tigated by prospective controlled studies.
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